AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

184.580

-0.230-0.12%

Volume:635.95K

Turnover:117.36M

Market Cap:88.40B

PE:-24.09

High:185.990

Open:185.000

Low:183.110

Close:184.810

52wk High:216.734

52wk Low:88.830

Shares:478.91M

Float Shares:478.91M

Volume Ratio:0.68

T/O Rate:0.13%

Dividend:4.18

Dividend Rate:2.27%

EPS(TTM):-7.662

EPS(LYR):-7.660

ROE:-15.83%

ROA:7.26%

PB:4.17

PE(LYR):-24.10

Loading ...

Overview Company News Filings

Lixudebart Deal Could Be A Game Changer For CSL (ASX:CSL)

Simply Wall St.

Is Building Envelope Expansion Altering The Investment Case For Carlisle Companies (CSL)?

Simply Wall St.

Australia's CSL Rises After Jefferies Sees Plasma Yield Upside

Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss

MT Newswires Live

Australia's CSL Set for Weekly Gain on Rare Diseases Drug Deal

CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform

MT Newswires Live

Carlisle Companies (CSL) Could Be 22% Undervalued Following Its Recent Pullback

Simply Wall St.

US Stocks on the MOVE-Palantir, Haemonetics

Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027

Haemonetics Says CSL Plasma Expects U.S. Rollout of Its Devices at All Centers by End-2027

Enters Agreement with Terumo Bct to Support Platform Transition

THOMSON REUTERS

Transition to Haemonetics Platform to Increase Plasma Collection Network Efficiency

THOMSON REUTERS

To Complete Haemonetics Platform Rollout in U.S. Plasma Centres by End 2027

THOMSON REUTERS

Expands Relationship with Haemonetics Corporation

THOMSON REUTERS

Citi Raises CSL's PT After $1.6 Billion Alentis Deal

CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds

Simply Wall St.

CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says

MT Newswires Live

Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon

THOMSON REUTERS

Settlement of Notes Expected on October 14, 2026

THOMSON REUTERS

CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/stock/CSL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":184.58,"timestamp":1791868320000,"preClose":184.81,"halted":0,"volume":635952,"delay":0,"changeRate":-0.0012445214003570682,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.661594105366854,"marketStatus":"Not Yet Opened","change":-0.23,"latestTime":"10-13 16:12:00 AEDT","open":185,"high":185.99,"low":183.11,"amount":117358575,"amplitude":0.015584,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.661594105366854,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":184.81,"dividendRate":0.022656,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":0.6835694476700072,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":184.81,"auctionPrice":184.56,"auctionVolume":190295,"auction":3,"marketStatus":"盘后竞价","timestamp":1791868217914}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.660388,"volumeRatio":0.6835694476700072,"shares":478911979,"dividePrice":4.180997,"high":185.99,"amplitude":0.015584,"preClose":184.81,"low":183.11,"week52Low":88.83,"pbRate":"4.17","psRate":"3.91","week52High":216.734,"institutionHeld":0,"latestPrice":184.58,"eps":-7.661594105366854,"divideRate":0.022651,"volume":635952,"delay":0,"ttmEps":-7.661594105366854,"open":185,"prevYearClose":168.21,"prevWeekClose":183.84,"prevMonthClose":184.22,"prevQuarterClose":184.22,"fiveDayClose":178.68,"twentyDayClose":174.26,"sixtyDayClose":119.81,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675369129","title":"Lixudebart Deal Could Be A Game Changer For CSL (ASX:CSL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369129","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675369129?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:25","pubTimestamp":1791894339,"startTime":"0","endTime":"0","summary":"CSL and Alentis Therapeutics previously announced an exclusive global collaboration to co-develop and co-promote lixudebart, with US$355 million upfront, up to US$1.2b in commercial milestones, CSL-funded Phase 2 and Phase 3 programs, and a 55% to 45% global profit split in favour of CSL once commercialised.\nThe alliance gives CSL broader exposure to claudin-1 targeting therapies in rare kidney and liver diseases while outsourcing part of early scientific risk to Alentis. This aligns with...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/lixudebart-deal-could-be-a-game-changer-for-csl-asxcsl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/lixudebart-deal-could-be-a-game-changer-for-csl-asxcsl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7511","CSL.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899595","title":"Is Building Envelope Expansion Altering The Investment Case For Carlisle Companies (CSL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899595","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674899595?lang=en_us&edition=fundamental","pubTime":"2026-10-10 15:33","pubTimestamp":1791617605,"startTime":"0","endTime":"0","summary":"Carlisle Companies is seeing strong demand in its Carlisle Construction Materials and Carlisle Weatherproofing Technologies units, while expanding its building envelope portfolio through acquisitions such as Bonded Logic and ThermaFoam and continuing a 50 year streak of dividend increases.\nThe decision to lift the 2026 share repurchase target and extend a multi decade record of dividend growth indicates that Carlisle Companies is placing significant emphasis on capital return alongside...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-building-envelope-expansion-altering-the-investment-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-building-envelope-expansion-altering-the-investment-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169589451.USD","SG9999004303.SGD","BK7501","LU0728928796.USD","BK7067","CSL.AU","BK7511","BK7508","LU1169590202.USD","BK4086","CSL","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674688773","title":"Australia's CSL Rises After Jefferies Sees Plasma Yield Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2674688773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674688773?lang=en_us&edition=fundamental","pubTime":"2026-10-09 11:31","pubTimestamp":1791516691,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises after Jefferies sees plasma yield upside** Shares of Australia's CSLCSL.AXrise as much as 1.62% to A$184.4** Jefferies says the biotechnology giant remains rated \"hold\", after its US plasma platform shift may lift efficiency but risks collection disruption** Brokerage says CSL will replace Terumo systems with Haemonetics equipment across about 330 US centres by the end of 2027** Jefferies notes channel checks suggest the new platform can deliver up to a 15% improvement in plasma collection yield** Adds a single newer platform is aligned with CSL's cost-per-litre and gross margin goals, though benefits are likely to emerge gradually** Jefferies says \"the key risks are collection disruption during the changeover\" and is watching for any disclosure of costs, savings and impairment** Stock for the week up 5.1% and putting the stock on track for its best week in a month","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nL6N45V057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE","LU1169590202.USD","IE00B64QTZ34.USD","BK7501","BK7067","CSL.AU","LU0012050646.USD","IE00BLDYK493.USD","LU0205194284.USD","BK4198","LU1169589451.USD","LU0106261612.USD","BK7508","LU0205193047.USD","IE0034390439.USD","BK7511","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827878","title":"Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827878","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674827878?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:46","pubTimestamp":1791513965,"startTime":"0","endTime":"0","summary":"Terumo  has mutually agreed with CSL Plasma to end their supply agreement for source plasma collection devices, and expects a loss of $610 million, according to a Thursday Tokyo bourse filing.The loss comprises $450 million in non-cash impairment losses and $160 million in transition, termination, and restructuring costs.Subsequently, Terumo revised its full-year guidance for the fiscal year ending March 31, 2027, cutting profit attributable to owners of the parent to 120 billion yen from 193.1 billion yen initially.Basic earnings per share estimates dropped to 81.35 yen from 130.91 yen, while revenue targets were cut to 1.23 trillion yen from 1.239 trillion yen.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK7067","BK7501","YCL","BK7508","CSL.AU","HEWJ","FXY","YCS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674788109","title":"Australia's CSL Set for Weekly Gain on Rare Diseases Drug Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2674788109","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674788109?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:27","pubTimestamp":1791509229,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL set for weekly gain on rare diseases drug deal** Shares of biotech firm CSLCSL.AXup over 4.8% so far this week, on track for best week since mid-September** On Monday, CSL said it","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nL4N45V01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674880588","title":"CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2674880588","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674880588?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:26","pubTimestamp":1791494795,"startTime":"0","endTime":"0","summary":"CSL  said it will transition its US plasma collection centers to Haemonetics' latest-generation plasmapheresis platform, with the rollout expected to be completed by the end of 2027, according to an Australian bourse filing on Thursday after market hours.The company has also reached an agreement with Terumo BCT, the provider of its current Rika system, to ensure a smooth transition, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4198","HAE","LU1169589451.USD","BK7067","BK7511","BK7508","BK7501","IE00B19Z6F94.USD","LU0012050646.USD","CSL.AU","IE0034390439.USD","LU1169590202.USD","LU0205194284.USD","IE00BLDYK493.USD","IE00B64QTZ34.USD","LU0106261612.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007641","title":"Carlisle Companies (CSL) Could Be 22% Undervalued Following Its Recent Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007641?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:29","pubTimestamp":1791487783,"startTime":"0","endTime":"0","summary":"Carlisle Companies (CSL) has come back into focus after a recent share price slide, with the stock down about 10% over the past month and roughly 4% over the past year.\nThe recent slide comes after a softer few months for Carlisle Companies, with the share price down over the past quarter and its 1-year total shareholder return slightly negative despite strong multi year gains. That pattern suggests momentum has cooled as investors reassess growth prospects and risk, rather than responding to...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-could-be-22-undervalued-following-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-could-be-22-undervalued-following-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","BK7067","CSL","LU1169590202.USD","BK4086","LU1169589451.USD","LU0728928796.USD","SG9999004303.SGD","CSL.AU","BK7501","BK7508","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674042200","title":"US Stocks on the MOVE-Palantir, Haemonetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2674042200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674042200?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:15","pubTimestamp":1791483328,"startTime":"0","endTime":"0","summary":"BUZZ-US STOCKS ON THE MOVE-Palantir, HaemoneticsOct 8 (Reuters)-US stocks fell on Thursday as a surge in oil prices and Treasury yields near multi-year highs stoked inflation worries before a crucial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL6N45U0PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLYE","HUT","LITE","MANE","OXY","MARA","STZ","DVN","RIOT","BETR","HELE","CVX","HAE","BE","COIN","HUBS","GDDY","HSIC","OLED","FEDU","COHR","HNRG","PLTR","RNA","COP","PM","CSGP","09311","IONQ","APLD","GFS","PCRX","GNRC","SBUX","XOM","PEP","CSL.AU","CMG","AMTD","MO","GLAS","SBFM","VTRS","DKI","RCL","AIXI","LEVI","CABO","JZ","SXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673907746","title":"Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673907746","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673907746?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:50","pubTimestamp":1791463800,"startTime":"0","endTime":"0","summary":"Shares of Haemonetics rose after CSL Plasma said it expects to complete the rollout of the company's devices and disposables under their supply agreement by the end of 2027.The stock gained 16% to $118 in premarket trading Thursday. At Wednesday's market close, shares were up 27% year to date.Under the supply agreement, which the companies entered in August, CSL can use Haemonetics' NexSys PCS devices and purchase related disposables in the U.S. Haemonetics said at the time the supply agreement was non-exclusive and did not contain minimum purchase commitments.In a Thursday filing with the Securities and Exchange Commission, Haemonetics said CSL expects the transition to its devices and disposables will occur at all of CSL's current U.S. plasma collection centers.The scope and timing of the rollout remain subject to change, Haemonetics said, noting it is not updating its previously issued fiscal 2027 guidance at this time.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","LU0012050646.USD","BK7511","BK7067","IE00BLDYK493.USD","BK4198","LU0106261612.USD","BK7501","LU0205193047.USD","LU0205194284.USD","HAE","LU1169590202.USD","BK7508","IE0034390439.USD","CSL.AU","LU1169589451.USD","IE00B64QTZ34.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673075157","title":"Haemonetics Says CSL Plasma Expects U.S. Rollout of Its Devices at All Centers by End-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673075157","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673075157?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:16","pubTimestamp":1791454562,"startTime":"0","endTime":"0","summary":"Haemonetics says CSL Plasma expects U.S. rollout of its devices at all centers by end-2027Haemonetics disclosed an update on its non-exclusive U.S. supply agreement with CSL Plasma for NexSys PCS devi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL2PrFZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLDYK493.USD","IE00B19Z6F94.USD","LU0106261612.USD","LU0205193047.USD","IE0034390439.USD","BK4198","LU0205194284.USD","HAE","BK7508","CSL.AU","IE00B64QTZ34.USD","LU1169590202.USD","BK7511","BK7501","LU0012050646.USD","LU1169589451.USD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673402107","title":"Enters Agreement with Terumo Bct to Support Platform Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2673402107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673402107?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673210760","title":"Transition to Haemonetics Platform to Increase Plasma Collection Network Efficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2673210760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673210760?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7501","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071021","title":"To Complete Haemonetics Platform Rollout in U.S. Plasma Centres by End 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673021079","title":"Expands Relationship with Haemonetics Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673021079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673021079?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CSL.AU","BK7511","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017859","title":"Citi Raises CSL's PT After $1.6 Billion Alentis Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017859?lang=en_us&edition=fundamental","pubTime":"2026-10-08 02:43","pubTimestamp":1791398609,"startTime":"0","endTime":"0","summary":"BUZZ-Citi raises CSL's PT after $1.6 billion Alentis deal** Citi raises PT of Australia's CSLCSL.AXto A$180, sees upside in deal with Alentis** On Monday, the biotech giantsignedan agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion** Brokerage says the deal is consistent and structurally sound aligning with company commentary** Says deal sticks within an area CSL already operates - orphan renal conditions** Sees $125 million risk adjusted sales by 2031, addresses that pipeline replenishment is a key concern for investors and sees this as a positive step** 10 of 17 analysts rate the stock \"buy\" or higher, seven \"hold\"; their median PT is A$182, LSEG-compiled data shows** YTD, stock up nearly 5.5%, as of last close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T14G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673019013","title":"CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673019013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673019013?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:38","pubTimestamp":1791383882,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has entered into an exclusive partnership with Alentis Therapeutics to co-develop lixudebart, supporting the antibody with a US$355 million upfront payment and up to US$1.2 billion in potential milestone payments.\nCSL shares have been on a strong run recently, with the 90 day share price return of 44.98% and 30 day share price return of 5.09% suggesting momentum has picked up after a weaker patch. This comes even though the 1 year total shareholder return is still down 9.23% and...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK7511","BK7501","ISBC","CSL.AU","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673671490","title":"CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673671490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673671490?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:10","pubTimestamp":1791346251,"startTime":"0","endTime":"0","summary":"CSL's  deal with Alentis Therapeutics for Lixudebart, a therapy candidate for anti-neutrophil cytoplasmic antibodies-associated vasculitis and rapidly progressive glomerulonephritis, is low-risk but low-reward, RBC Capital Markets said in a Thursday note.It noted that the clinical and commercial aspects of Lixudebart are unknown and the timeframe to first potential commercial revenues is fairly long. The deal's PoS adjusted net present value is AU$415 million.RBC reduced CSL's earnings per share forecasts by 0.1% to 0.4% for fiscal 2027 to fiscal 2029.The brokerage assigned an outperform rating to CSL and raised the price target to AU$215 from AU$213.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","LU0128525929.USD","BK7067","GSIB","LU0029864427.USD","LU1267930573.SGD","LU0310800379.SGD","BK4207","CSL.AU","BK7501","BK7508","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673662090","title":"Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673662090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673662090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673306620","title":"Settlement of Notes Expected on October 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673306620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673306620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7501","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673208066","title":"CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673208066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673208066?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7501","BK7508","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}